Phase I/II study to evaluate the efficacy and safety of PAZOPANIB in combination with TEMOZOLOMIDE as maintenance therapy in Glioblastoma patients undergoing surgery and subsequently treated with induction radiotherapy-TEMOZOLOMIDE
Phase 1
- Conditions
- gliobastomaTherapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2024-510960-22-00
- Lead Sponsor
- Centre Antoine Lacassagne
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 51
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method